Correction to: Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively (CNS Drugs, (2021), 35, 7, (703-716), 10.1007/s40263-021-00832-x)

Abstract

In the original publication, page 705, column 1—the sentence at the end of the first paragraph that read: “The actuarial risk of severe cerebrovascular events (including deaths) due to hypertensive reactions is low, variously estimated as lying between 0.0014 and 0.007% [24-26] (i.e. 140-700 events per 100,000 patients treated).” should read “The actuarial risk of severe cerebrovascular events (including deaths) due to hypertensive reactions is low, variously estimated as lying between 0.00143 and 0.007% [24-26] (i.e. 1.43-7.0 events per 100,000 patients treated).”